Nomenclature	FPR1	FPR2/ALX	FPR3
HGNC, UniProt	FPR1, P21462	FPR2, P25090	FPR3, P25089
Principal transduction	Gi/o, Gz	Gi 778	–
Rank order of potency	fMet-Leu-Phe > cathepsin G (CTSG, P08311) > annexin I 776,783	LXA4=aspirin triggered lipoxin A4=ATLa2>LTC4=LTD4>>15-deoxy-LXA4>>fMet-Leu-Phe 765,766,768,770,784	–
Selective agonists (pKi)	fMet-Leu-Phe (pEC50 10.1–10.2) 769,782	–	–
Endogenous antagonists (pKi)	spinorphin (Selective) (pIC50 4.3) 777,780	aspirin triggered lipoxin A4 (Selective), LXA4 (Selective) (pEC50 ∼12.0) 775, resolvin D1 (Selective) (pEC50 ∼11.9) 775	–
Endogenous agonists(pKi)	F2L (HEBP1, Q9NRV9) (Selective) (pEC50 8.0–8.2) 779	–	–
Selective antagonists (pKi)	cyclosporin H (6.1–7.1) 785,786, t-Boc-FLFLF (6.0–6.5) 785	ATLa2 771	–
Radioligands (Kd)	[3H]fMet-Leu-Phe (Agonist, Full agonist) (5×10−10–2.51×10−8 M) 774	[3H]LXA4 (Agonist, Full agonist) (5×10−10–7×10−10 M) 766,767	–
Comment	A FITC-conjugated fMLP analogue has been used for binding to the mouse recombinant receptor 773	The agonist activity of the lipid mediators described has been questioned 772,781, which may derive from batch-to-batch differences, partial agonism or biased agonism	–